Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974723 · ClinicalTrials.gov registry record
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
A clinical trial, sponsored by Radius Health.
- Completed
- Registry status
- 22,054
- Enrollment target
NCT04974723: Completed study, sponsored by Radius Health.
NCT04974723 is a clinical trial that has completed, run by Radius Health. The registered enrollment target is 22,054 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04974723 has completed, sponsored by Radius Health.
- COMPLETED
- Registry status
- 22,054 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts
Primary Outcome
A nonvertebral fracture is any fragility fracture at the hip, pelvis, femur, ankle, shoulder (including shoulder, humerus, clavicle), radius/ulna, wrist, or tibia/fibula. The date of the first prescription claim for either abaloparatide or teriparatide during the identification period was considered the index date. A claims-based algorithm with high specificity for fracture site was used to identify osteoporosis related fractures. Patients were followed for up to 18 months after their index date
Interventions
- DRUG Abaloparatide
- DRUG Teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,054 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2021-09-30 |
What the finished NCT04974723 record still lists
NCT04974723 is an observational study that tracks outcomes without assigning an intervention. Its 22,054 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Abaloparatide is the first listed.
NCT04974723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04974723 about?
NCT04974723 is a clinical study titled "Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women". The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts
What is the current status of trial NCT04974723?
This trial is currently completed. The enrollment target is 22,054 participants. The study started on 2021-07-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04974723?
The interventions under investigation include: Abaloparatide (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT04974723?
This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI